Insmed Inc (NASDAQ:INSM)

21.96
Delayed Data
As of May 28
 -0.39 / -1.74%
Today’s Change
11.25
Today|||52-Week Range
24.00
+41.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.4B

Company Description

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Its main product ARIKAYCE or LAI, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. Insmed was founded on November 29, 1999 and is headquartered in Monmouth Junction, NJ.

Contact Information

Insmed, Inc.
Building 10
Bridgewater New Jersey 08807-3365
P:(908) 977-9900
Investor Relations:

Employees

Shareholders

Other institutional54.81%
Individual stakeholders5.11%
Mutual fund holders33.51%

Top Executives

William H. LewisPresident, Chief Executive Officer & Director
Andrew T. DrechslerChief Financial Officer
Walter R. PerkinsChief Technology Officer
Gina EagleVice President-Clinical Research
Eugene Jeffrey SullivanChief Medical & Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account